Bioventix Plc Director/PDMR Shareholding

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                          Director/PDMR Shareholding 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, was notified on 25 October 2019 of the following 
transaction in its ordinary shares of 5 pence each ("Ordinary Shares"): 
 
Director          Position       Ordinary    Sale price      Ordinary Percentage of 
                                   Shares  per Ordinary   Shares held  issued share 
                                     sold         Share  subsequently  capital held 
                                                                       subsequently 
 
Ian Nicholson and Non-Executive     2,500     3,158.67p        15,500          0.3% 
Persons Closely   Chairman 
Associated 
 
   Notification and public disclosure of transactions by persons discharging 
     managerial responsibilities and persons closely associated with them 
 
1.         Details of the person discharging managerial responsibilities / 
           person closely associated 
 
a)         Names                   Ian Nicholson (Non-Executive Chairman) 
 
2.         Reason for the Notification 
 
a)         Position/status         See 1(a) above 
 
b)         Initial notification/   Initial notification 
           Amendment 
 
3.         Details of the issuer, emission allowance market participant, auction 
           platform, auctioneer or auction monitor 
 
a)         Name                    Bioventix plc 
 
b)         LEI                     213800225MHX7LZQY108 
 
4.         Details of the transaction(s): section to be repeated for (i) each 
           type of instrument; (ii) each type of transaction; (iii) each date; 
           and (iv) each place where transactions have been conducted 
 
a)         Description of the      Ordinary shares of 5 pence ("Ordinary 
           Financial instrument,   Shares") 
           type of instrument 
 
           Identification code     GB00B4QVDF07 
 
b)         Nature of the           Sale of Ordinary Shares 
           transaction 
 
c)         Price(s) and volume(s)  Price(s)              Volume(s) 
 
                                   3,158.67p             2,500 
 
d)         Aggregated information: See 4(c) 
           ·      Aggregated 
           volume 
           ·      Price 
 
e)         Date of the transaction 25 October 2019 
 
f)         Place of the            London Stock Exchange, AIM Market (XLON) 
           transaction 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
The information communicated in this announcement contains inside information 
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. 
 
 
 
END
(END) Dow Jones Newswires
October 28, 2019 11:00 ET (15:00 GMT)
Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025